Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
Zogenix saw its stock drop as much as 16% on Tuesday, after it announced an acquisition of a privately held California start-up launched just 10 months ago with $30 million Series A investment led by F-Prime Capital Partners and OrbiMed. 28 August 2019
Biotechnology
Privately-held Immatics Biotechnologies today announced that it has entered into a strategic collaboration and option agreement to develop novel adoptive cell therapies targeting multiple cancers with US biotech major Celgene. 28 August 2019
Biotechnology
The European Commission (EC) has approved the extension of the current marketing authorization of Solaris (eculizumab) to include the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease, making it the first and only drug cleared for this condition in Europe. 28 August 2019
Biotechnology
The European Commission (EC) has now approved Empliciti (elotuzumab) plus pomalidomide and low-dose dexamethasone (EPd) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM). 28 August 2019
Biotechnology
T-cell therapy company Adaptimmune Therapeutics has announced a collaboration with Japanese biotech Noile-Immune. 27 August 2019
Biotechnology
Privately-owned precision medicine company Machavert Pharmaceuticals has obtained a full exclusive license on RAL GTPase (RAL) inhibitors from the University of Colorado. 27 August 2019
Biotechnology
US RNA-targeted drug developer Ionis Pharmaceuticals says that GlaxoSmithKline has exercised its option to license Ionis' antisense medicines for people with chronic hepatitis B virus (CHB) infection following positive Phase II results. 27 August 2019
Biotechnology
US pharma major Eli Lilly saw its shares close up 2.07% at $111.78 yesterday, after it revealed that the US regulator had cleared its interleukin (IL)-17A-targeting antibody Taltz (ixekizumab) for a third indication. 27 August 2019
Biotechnology
Specialty pharma company US WorldMeds has had its supplemental Biologics License Application (sBLA) approved for Myobloc (rimabotulinumtoxinB) injection for the treatment of chronic sialorrhea in adults. 27 August 2019
Biotechnology
ReveraGen BioPharma today announced positive study data with vamorolone in patients with Duchenne muscular dystrophy (DMD). 27 August 2019
Biotechnology
Complying with US Federal Trade Commission requirements, US biotech major Amgen has reached agreement with Celgene to acquire worldwide rights to the latter’s Otezla (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis. 26 August 2019
Biotechnology
UK-based scientists believe that they may have found a way to pull down the protective wall that surrounds tumors, potentially re-exposing them to the killing power of the immune system and immunotherapy treatments. 26 August 2019
Biotechnology
The American Arbitration Association Tribunal has dismissed claims from France’s Adocia that Eli Lilly misappropriated and misused company secrets. 23 August 2019
Biotechnology
Privately-held US biotech HotSpot Therapeutics today announced the acquisition of Macroceutics, a provider of DNA-encoded library (DEL) screening technologies. 23 August 2019
Biotechnology
Privately-held Swedish biotech OxThera today announced that, based on a positive opinion from the Pediatric Committee (PDCO), the European Medicines Agency has agreed to the proposed pediatric investigation plan (PIP) for Oxalobacter formigenes in the treatment of primary hyperoxaluria (PH). 23 August 2019
Biotechnology
The UK’s departure from the European Union looks likely to dent many sectors at least in the short to medium term, but the biopharmaceutical industry is one that might just continue to shine, however damaging the exit from the trade bloc proves to be. 23 August 2019
Biotechnology
There was bad news for Retrophin yesterday relating to its lead pipeline candidate fosmetpantotenate, sending the Shkreli-founded biotech’s shares plummeting as much as 32% to $11.84, and leading to speculation that the company is ripe for takeover. 23 August 2019
Biotechnology
Of the one in ten American adults diagnosed with diabetes, over a tenth do not fully comply with the doctor’s orders, in order to save on prescription costs. 22 August 2019
Biotechnology
The latest approval for Darzalex (daratumumab), a multiple myeloma drug from Danish biotech Genmab and its big pharma partner Janssen, has come in Japan in the frontline setting. 22 August 2019
Biotechnology
Privately-owned Austrian biotech Themis Bioscience announced today a research collaboration and exclusive license agreement with Merck & Co, known as MSD outside the USA and Canada, for the discovery and development of undisclosed vaccine candidates using Themis’ measles virus vector-based platform, marking the Vienna-based firm’s first deal with a pharma major. 22 August 2019
All news
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze